For example, in HCT116 cells treated with chemotherapies 5-FU, irinotecan, oxaliplatin, cisplatin, or clinically relevant combinations, the soluble form of the p53 target TRAIL-R2 was downregulated in a drug-specific manner (Carlsen et al., 2021), but in breast cancer cells was upregulated in a pan-drug manner (Groysman et al., 2021). This evidence concerns the gene TP53 and breast carcinoma.